Dravet Syndrome (SMEI) Clinical Trials and Treatments

Dravet Syndrome represents one of the most severe forms of childhood-onset epilepsy, caused primarily by loss-of-function mutations in the SCN1A gene. This gene encodes the Nav1.1 alpha subunit of voltage-gated sodium channels essential for neuronal excitability. The disease typically begins with a prolonged febrile seizure, often the first febrile convulsion the child experiences, occurring without warning during a fever.

The most common symptoms of Dravet Syndrome include First seizures typically occur between 6 months and 3 years of age, often triggered by fever, Prolonged seizures lasting more than 30 minutes (febrile status epilepticus), Multiple types of seizures: generalized tonic-clonic, myoclonic, atypical absence, and focal seizures, Developmental delay and intellectual disability, Speech and language difficulties, among others. Approximately 1 in 16,000 to 40,000 people, accounting for 5-10% of early infantile epileptic encephalopathies. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Dravet Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Dravet Syndrome research is advancing with FDA-approved medications like stiripentol and cannabidiol showing efficacy, and ongoing trials investigating additional cannabinoid-based treatments, gene therapy approaches, and sodium channel modulators. Clinical trials are also exploring antisense oligonucleotides and other molecular approaches to restore SCN1A function.

Yes. As of October 21, 2026, 3 FDA-approved medicines have a current label that names Dravet Syndrome: Diacomit (stiripentol), first approved in 2018; Epidiolex (cannabidiol), first approved in 2018; and Fintepla (fenfluramine), first approved in 2020. Corticosteroids and immune globulins count once each.

Dravet syndrome is caused by loss-of-function mutations in the SCN1A gene, which encodes the alpha subunit of the NaV1.1 voltage-gated sodium channel. NaV1.1 is predominantly expressed in GABAergic inhibitory interneurons, so loss-of-function mutations reduce the ability of these neurons to fire action potentials. This creates an excitation-inhibition imbalance that drives seizures. Sodium channel blocker medications (carbamazepine, lamotrigine, phenytoin, oxcarbazepine) are contraindicated because they further suppress the already-impaired inhibitory neurons, worsening seizure frequency and severity.

Dravet syndrome is caused by mutations in the SCN1A gene in approximately 80-90% of cases. SCN1A encodes the NaV1.1 voltage-gated sodium channel, essential for inhibitory interneuron function. Over 1,800 distinct SCN1A mutations have been identified, including missense (~46%), frameshift (~27%), nonsense (~13%), and splice site (~11%) variants. Approximately 90% of cases arise from de novo mutations. Genetic testing through SCN1A sequencing is required for enrollment in precision medicine trials like zorevunersen (STK-001) and ETX101. Gain-of-function variants (associated with GEFS+ rather than classic Dravet) are typically excluded from these trials.

Eligibility for Dravet Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Dravet Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.

Dravet syndrome medication conflicts require special attention because some common anti-seizure drugs are actually contraindicated in Dravet. Trial Friend's medication conflict checker scans each trial's exclusion criteria against Dravet treatments in three categories. FDA-approved Dravet therapies: cannabidiol (Epidiolex), fenfluramine (Fintepla), and stiripentol (Diacomit). First-line and adjunctive medications: valproic acid (Depakote), clobazam (Onfi/Sympazan), topiramate (Topamax), levetiracetam (Keppra), and clonazepam (Klonopin). Contraindicated sodium channel blockers: carbamazepine (Tegretol), lamotrigine (Lamictal), phenytoin (Dilantin), and oxcarbazepine (Trileptal), which are known to worsen seizures in Dravet and should be discussed with your neurologist regardless of trial participation. Most Dravet trials allow participants to continue stable anti-seizure medications, but precision medicine trials like zorevunersen (STK-001) and ETX101 may have additional eligibility requirements around genetic confirmation and specific drug classes.

Key questions for your child's doctor about Dravet clinical trials include: Does my child's specific SCN1A mutation type affect which trials qualify? Can she participate while continuing current seizure medications like Epidiolex, Fintepla, or Depakote? What is the difference between the antisense oligonucleotide approach (zorevunersen) and the gene therapy approach (ETX101)? Is she on any sodium channel blockers that should be discontinued? Are there age restrictions for current trials? The Dravet Syndrome Foundation tracks current research and trial opportunities.